-Reuters
BTIG Maintains Buy on Axsome Therapeutics, Raises Price Target to $98
BTIG analyst Robert Hazlett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $62 to $98.
Related Posts
Raymond James Upgrades Cushman & Wakefield to Strong Buy, Announces $31 Price Target
Raymond James analyst Patrick O'Shaughnessy upgrades Cushman & Wakefield (NYSE:CWK) from Outperform to Strong Buy and announces $31 price target.
Apple Supplier Pegatron Joins Hands With Microsoft For 5G Private Networks: Report
Taiwan-based Pegatron Corp, a key Apple Inc (NASDAQ: AAPL) supplier, is joining hands with Microsoft Corp (NASDAQ: MSFT) to deploy 5G private networks as it looks to tap
Fire Flower Launches Next Business Day Cannabis Deliveries In Metro Vancouver Area
Pineapple Express Delivery Inc., a subsidiary of Fire & Flower Holdings Corp.'s (TSX:FAF) (OTCQX: FFLWF) will begin offering next business day delivery through BC Cannabis Stores' e-commerce website in the Metro Vancouver region beginning the week of Feb. 28, 2022.